The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schreurs, M. W. J.
Right arrow Articles by Hooijberg, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schreurs, M. W. J.
Right arrow Articles by Hooijberg, E.
The Journal of Immunology, 2003, 171: 2912-2921.
Copyright © 2003 by The American Association of Immunologists

In Vitro Generation and Life Span Extension of Human Papillomavirus Type 16-Specific, Healthy Donor-Derived CTL Clones 1

Marco W. J. Schreurs, Kirsten B. J. Scholten, Esther W. M. Kueter, Janneke J. Ruizendaal, Chris J. L. M. Meijer and Erik Hooijberg2

Department of Pathology, Vrije Universiteit Medical Center, 1081 HV Amsterdam, The Netherlands

Human papillomavirus (HPV) type 16 infection is strongly associated with the development of cervical carcinoma (CxCa) in women. The HPV16-derived oncoproteins E6 and E7, responsible for both onset and maintenance of malignant transformation, are expressed constitutively in CxCa cells and represent tumor-associated Ags. As a result, E6 and E7 constitute potential targets for adoptive CTL-mediated immunotherapy of CxCa. However, the availability to date of well-characterized HPV16-specific, CxCa-reactive human CTLs is extremely limited. The current study describes the in vitro generation and isolation of HPV16 E7-specific, CxCa-reactive human CTL clones from low-frequency healthy donor-derived CD8{beta}-positive precursors. For this purpose, an in vitro CTL induction protocol was used involving mature monocyte-derived dendritic cells as stimulator cells loaded with an HLA-A2.1-restricted, E711–20-derived high-affinity altered peptide ligand. A double tetramer-guided isolation procedure and subsequent limiting-dilution cloning resulted in Ag-specific CTL clones. Stringent CTL characterization clearly indicated Ag-specific, HLA-A2.1-restricted reactivity against different HPV16-transformed CxCa cell lines. To allow expansion of E711–20-specific CTL clones to numbers required for prolonged in vitro as well as in vivo application, their life span was significantly extended by ectopic expression of human telomerase reverse transcriptase. Collectively, our results show that optimized CTL induction and stringent CTL selection procedures, followed by human telomerase reverse transcriptase-mediated life span extension will allow continued availability of low-frequency HPV16-specific, CxCa-reactive human CTL clones. This may enhance the prospects of HPV16-specific adoptive CTL immunotherapy in CxCa patients.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Moreno, J. W. Molling, S. von Mensdorff-Pouilly, R. H. M. Verheijen, E. Hooijberg, D. Kramer, A. W. Reurs, A. J. M. van den Eertwegh, B. M. E. von Blomberg, R. J. Scheper, et al.
IFN-{gamma}-Producing Human Invariant NKT Cells Promote Tumor-Associated Antigen-Specific Cytotoxic T Cell Responses
J. Immunol., August 15, 2008; 181(4): 2446 - 2454.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. J. A. M. Santegoets, H. J. Bontkes, A. G. M. Stam, F. Bhoelan, J. J. Ruizendaal, A. J. M. van den Eertwegh, E. Hooijberg, R. J. Scheper, and T. D. de Gruijl
Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model
J. Immunol., April 1, 2008; 180(7): 4540 - 4549.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. J. A. M. Santegoets, M. W. J. Schreurs, A. W. Reurs, J. J. Lindenberg, E. W. M. Kueter, A. J. M. van den Eertwegh, E. Hooijberg, R. J. Brandwijk, S. E. Hufton, H. R. Hoogenboom, et al.
Identification and Characterization of ErbB-3-Binding Protein-1 as a Target for Immunotherapy
J. Immunol., August 1, 2007; 179(3): 2005 - 2012.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
D.-W. Liu, Y.-C. Yang, H.-F. Lin, M.-F. Lin, Y.-W. Cheng, C.-C. Chu, Y.-P. Tsao, and S.-L. Chen
Cytotoxic T-Lymphocyte Responses to Human Papillomavirus Type 16 E5 and E7 Proteins and HLA-A*0201-Restricted T-Cell Peptides in Cervical Cancer Patients
J. Virol., March 15, 2007; 81(6): 2869 - 2879.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Houtenbos, T. M. Westers, A. Dijkhuis, T. D. de Gruijl, G. J. Ossenkoppele, and A. A. van de Loosdrecht
Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting
Clin. Cancer Res., January 1, 2007; 13(1): 307 - 315.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Menzel, M. Migliaccio, D. R. Goldstein, S. Dahoun, M. Delorenzi, and N. Rufer
Mechanisms Regulating the Proliferative Potential of Human CD8+ T Lymphocytes Overexpressing Telomerase
J. Immunol., September 15, 2006; 177(6): 3657 - 3668.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. W. J. Schreurs, M. A. J. A. Hermsen, R. I. K. Geltink, K. B. J. Scholten, A. A. T. P. Brink, E. W. M. Kueter, M. Tijssen, C. J. L. M. Meijer, B. Ylstra, G. A. Meijer, et al.
Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes
Blood, October 15, 2005; 106(8): 2663 - 2670.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Preville, D. Ladant, B. Timmerman, and C. Leclerc
Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein
Cancer Res., January 15, 2005; 65(2): 641 - 649.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.